Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP

Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP


Akorn, Inc. , a leading specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Mycophenolate Mofetil for Injection, USP, 500 mg/vial. This approval is the first new product approval received out of Akorn's Decatur, Illinois manufacturing facility since the FDA re-inspection in December 2016.



from Biotech News